Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 4Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Cisplatin 11Pemetrexed 10pembrolizumab 9Nivolumab 3LMB-100 3budigalimab 2belinostat 2amatuximab 2Paclitaxel 2Docetaxel 2Dexamethasone 2Cyclophosphamide 2Carboplatin 2Calcium Dobesilate 2venetoclax 1trametinib 1tislelizumab 1tazemetostat 1talazoparib 1spartalizumab 1sodium thiosulfate 1sargramostim 1ruxolitinib 1rovalpituzumab tesirine 1olaparib 1obinutuzumab 1naptumomab estafenatox 1irinotecan sucrosofate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma × LY3023414 × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡